CTI BioPharma Corp (NASDAQ:CTIC) major shareholder Bvf Partners L. P/Il bought 5,634,108 shares of the stock in a transaction dated Friday, February 9th. The shares were purchased at an average cost of $3.00 per share, for a total transaction of $16,902,324.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Shares of CTI BioPharma Corp (NASDAQ CTIC) opened at $3.54 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.17 and a current ratio of 2.19. CTI BioPharma Corp has a 12 month low of $2.45 and a 12 month high of $4.85. The stock has a market cap of $152.11, a PE ratio of -3.44 and a beta of 0.50.
Separately, Zacks Investment Research lowered shares of CTI BioPharma from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd.
WARNING: “CTI BioPharma Corp (CTIC) Major Shareholder Acquires $16,902,324.00 in Stock” was first published by Week Herald and is the property of of Week Herald. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://weekherald.com/2018/02/15/cti-biopharma-corp-ctic-major-shareholder-acquires-16902324-00-in-stock.html.
CTI BioPharma Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.